No Difference in Efficacy Between Ofatumumab, Rituximab in DLBCL
For relapsed or refractory diffuse large B-cell lymphoma, there is no difference in efficacy between ofatumumab or rituximab.
For treatment in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), there is no difference in efficacy between ofatumumab or rituximab when either is paired with cisplatin, cytarabine, and dexamethasone (DHAP) salvage therapy following autologous stem-cell transplantation (ASCT), according to a study published in the Journal of Clinical Oncology.1
Researchers evaluated 447 adult patients who had CD20-positive DLBCL who were refractory to first-line treatment with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) or experienced first relapse. The median age of the observed patients was 57 years; 63% had stage 3 or 4 disease.
The response rate was 38% for patients treated with ofatumumab and 42% for patients treated with rituximab. Post study-treatment ASCT was completed for 74 patients treated with ofatumumab (33%) and 83 patients treated with rituximab (37%).
Progression-free survival at 2 years was 24% for patients treated with ofatumumab and 26% for those treated with rituximab. Event-free survival at 2 years was 16% with ofatumumab and 18% for rituximab; overall survival at 2 years was 41% with ofatumumab and 38% with rituximab.
RELATED: Radioimmunotherapy for DLBCL: Clinical Outcomes Post-R-CHOP
“Characteristics of patients who enrolled in our study are representative of the typical patients who are encountered in daily practice who have experienced failure of first-line R-CHOP treatment and are deemed eligible for ASCT,” the authors noted.
- van Imhoff GW, McMillan A, Matasar MJ, et al. Ofatumumab versus rituximab salvage chemoimmunotherapy in relapsed or refractory diffuse large B-cell lymphoma: the ORCHARRD study. J Clin Oncol. 2016 Dec 28. doi: 10.1200/JCO.2016.69.0198 [Epub ahead of print]